Results 271 to 280 of about 9,809,915 (420)

Report of the Federation of European Laboratory Animal Science Associations Working Group on animal identification

open access: yesLaboratory Animals. Journal of the Laboratory Animal Science Association, 2013
K. Dahlborn   +5 more
semanticscholar   +1 more source

Abstracts of Technical Papers Presented at the Annual Meeting of the Canadian Society of Animal Science [PDF]

open access: bronze, 1998
John T. Ambrose   +22 more
openalex   +1 more source

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

open access: yesMolecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

第31回岡山実験動物研究会 [PDF]

open access: yes, 1997
Okayama Association for Laboratory Animal Science,
core  

Animal protection and medical science

open access: yesThe Lancet, 1994
Jennifer Leaning   +2 more
openaire   +4 more sources

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

open access: yesMolecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

表紙・目次 [PDF]

open access: yes, 2011
Okayama Association for Laboratory Animal Science,
core  

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

open access: yesMolecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy